Recent News

The latest news from the governments, medical industry and top online sources.

Meeting highlights from the Committee for Veterinary Medicin…

CVMP opinions on veterinary medicinal products  The Committee adopted a positive opinion for a marketing authorisation for Bexatil for the reduction of hyperglycaemia in cats with diabetes mellitus not previously treated with insulin. The Committee adopted a positive opinion for a variation for Mometamax Ultra to implement the outcome of the MAH’s signal management process to […]

Pluripotent stem cell trial for Huntington’s disease

Early-stage study marks milestone for regenerative medicine An update on the first clinical trial evaluating a pluripotent stem cell‑derived neural stem cell therapy for Huntington’s disease was presented at the ISSCR 2026 Annual Meeting, marking a significant step for regenerative medicine. The phase 1b/2a Regen4HD study follows years of preclinical work, safety testing and regulatory […]

Meeting highlights from the Committee for Medicinal Products…

Six new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended six medicines for approval at its June 2026 meeting. The committee recommended granting a marketing authorisation for Aujemflu (influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated), a vaccine to protect people aged 50 years and older against influenza. The CHMP recommended granting a marketing authorisation […]

NICE backs daratumumab quadruplet for newly diagnosed transp…

Final draft guidance recommends D‑VRd on the NHS in England and Wales NICE has issued final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D‑VRd) for adults with untreated multiple myeloma who are unsuitable for an autologous stem cell transplant. The decision means eligible patients in England and Wales will gain access to the […]

EMA, AMA and African regulatory authorities join forces on E…

EMA’s Emergency Task Force (ETF) is engaging with the African Medicines Agency (AMA) and its national regulatory authorities (NRAs), leveraging expertise from the WHO-AFRO African Vaccines Regulatory Forum (AVAREF), to discuss possible clinical trial designs and medical countermeasures to be investigated in the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and […]

Pierre Fabre Laboratories secures CHMP backing for first‑lin…

Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer Pierre Fabre Laboratories has received a positive opinion from the European Medicines Agency’s CHMP recommending approval of BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX for the first‑line treatment of adults with BRAFV600E‑mutant metastatic colorectal cancer. The opinion, which now passes to the European Commission for […]

EMA actively monitoring cruise ship Hantavirus outbreak

EMA is actively monitoring the ongoing hantavirus outbreak linked to a cruise ship, in coordination with other EU bodies. The virus has been identified as Andes hantavirus, the only hantavirus that can be transmitted person-to-person, typically requiring close, prolonged contact. Based on the available evidence so far, the European Centre for Disease Prevention and Control […]

UCB and Cancer Research UK form expanded alliance to advance…

Partnership builds on existing collaboration and adds two new UCB‑nominated projects UCB has entered a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, aiming to accelerate the development of novel oncology candidates by combining complementary scientific and clinical strengths. The agreement builds on a collaboration announced in 2023 […]

Meeting highlights from the Committee for Medicinal Products…

Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its April 2026 meeting. The committee recommended granting a marketing authorisation for Cenrifki (tolebrutinib), for the treatment of non-relapsing secondary progressive multiple sclerosis, a disease of the brain and spinal cord in which inflammation destroys the protective covering around […]

Transgene completes randomisation in phase 2 trial of tg4050

Company expects two‑year dfs data by q1 2028 Transgene has completed patient randomisation in the phase 2 part of its phase 1/2 clinical trial evaluating TG4050, an individualised neoantigen therapeutic vaccine being developed for the adjuvant treatment of head and neck cancer. The study has now enrolled 38 patients in the phase 2 cohort, with […]